uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
29 nov. 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Walking Fish Therapeutics Expands Leadership Team
01 juin 2023 09h00 HE
|
Walking Fish Therapeutics, Inc.
Promotes Julie Kim, PharmD, MS, to Chief Business Officer Appoints Nallakkan Arvindan, PhD, MBA, to Chief Technology Officer SOUTH SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Walking Fish...
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
19 janv. 2023 08h01 HE
|
Freeline Therapeutics Holdings plc
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in...
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
15 nov. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies ...
Freeline to Present at the Stifel Healthcare Conference
09 nov. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04 oct. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 août 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data Continued...
Enzyme Replacement Therapy Market Worth $15.18 Billion by 2028 at 6.8% CAGR Led by Hospitals Segment (49% Market Share in 2021) Global Analysis by The Insight Partners
22 juil. 2022 07h35 HE
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 16h01 HE
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
02 mai 2022 17h10 HE
|
Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...